Usa India Britain Mexico covid-19 vaccine novavax Usa India Britain Mexico

WHO approves Novavax as 10th authorised Covid jab

Reading now: 731
www.livemint.com

90% effective  WHO said Nuvaxovid was around 90-percent effective at reducing symptomatic cases of Covid-19 in two major clinical studies, one in Britain and the other in the United States and Mexico, involving more than 45,000 people.

In a separate document, WHO's Strategic Advisory Group of Experts on Immunisation recommended the new vaccine for use in people over the age of 18, with an interval of three to four weeks between the two doses. "The vaccine should not be administered with an interval of less than three weeks," it warned.

It can be kept at refrigerated temperatures between 2 and 8 degrees Celsius, giving it a logistical advantage in difficult-to-access regions over the mRNA vaccines, which must be stored at ultra-low

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA